TEVA Teva Pharmaceutical Industries
- Official Name: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Headquarters: 400 Interpace Parkway, Parsippany, NJ 07054, US
- CEO: Richard Francis
- Website: tevapharm.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Lost by 2.316 | (1.873) - 0.443 | ||
| 2025-07-15 | 1R | Lost by 2.881 | (1.791) - 1.090 | ||
| 2025-07-16 | 1R | Lost by 1.312 | (0.034) - 1.278 | ||
| 2025-07-22 | 2 | Lost by 1.259 | 1.284 - 2.543 | ||
| 2025-07-29 | 3 | Won by 2.726 | 1.896 - (0.830) | ||
| 2025-08-05 | 4 | Lost by 5.180 | 0.102 - 5.282 | ||
| 2025-08-12 | 5 | Won by 2.538 | 5.145 - 2.607 | ||
| 2025-08-19 | 6 | Won by 1.507 | 4.562 - 3.055 | ||
| 2025-08-26 | 7 | Won by 3.755 TOTW | 3.227 - (0.528) | ||
| 2025-09-02 | 8 | Won by 3.440 | 3.463 - 0.023 | ||
| 2025-09-09 | 9 | Won by 7.985 | 5.610 - (2.375) | ||
| 2025-09-16 | 10 | Lost by 3.902 | (5.242) - (1.340) | ||
| 2025-09-23 | 11 | Won by 3.208 | 4.062 - 0.854 | ||
| 2025-09-30 | 12 | Won by 11.395 TOTW | 4.220 - (7.175) | ||
| 2025-10-07 | 13 | Lost by 5.506 | (0.757) - 4.749 | ||
| 2025-10-14 | 14 | Lost by 3.673 | 0.229 - 3.902 | ||
| 2025-10-21 | 15 | Lost by 11.886 | (5.867) - 6.019 |
Latest News
Yahoo - 2026-10-15
Israel Elections: AI Stocks, A Defense Winner And Oil Prices In Focus
The Israeli elections later this month pit sitting Prime Minister Benjamin Netanyahu against a former general Gadi Eisenkot.
Benzinga - 2026-10-15
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.
Yahoo - 2026-10-13
Nvidia (NVDA) vs. Bumble (BMBL): How the AI Gold Rush is Blinding Investors to Real-Value Gems
The financial markets are currently gripped by a singular obsession: artificial intelligence. This manic focus has pushed sector leaders like Nvidia (...
Yahoo - 2026-10-13
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.
Yahoo - 2026-10-13
MedinCell (ENXTPA:MEDCL) Stock Could Be Overvalued On FDA Approval News
MedinCell has seen its share price move sharply in recent years, and the latest headlines around its U.S. product launch plans put fresh attention on ...
Yahoo - 2026-10-12
Teva to Host R&D Day on Wednesday, November 11 in New York City
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&a...
Yahoo - 2026-10-12
TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament
Teva Pharmaceutical stock rallied Friday on FDA approval for Weltruza. But is it already too late to invest in TEVA shares? Let’s find out!
Yahoo - 2026-10-12
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expect...
Yahoo - 2026-10-12
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs
Hardman Johnston Global Advisors, an investment management firm, issued its Q3 2026 investor letter for the “Hardman Johnston International Equity D...
Yahoo - 2026-10-12
FDA approves Teva’s monthly injection of olanzapine for schizophrenia
Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.
Show more
Yahoo - 2026-10-09
Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says
SeekingAlpha - 2026-10-09
Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy
Yahoo - 2026-10-09
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
SeekingAlpha - 2026-10-09
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - Slideshow
Yahoo - 2026-10-09
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
SeekingAlpha - 2026-10-09
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
Benzinga - 2026-10-09
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
Yahoo - 2026-10-09
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
Benzinga - 2026-10-09
Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
Yahoo - 2026-10-08
Teva (TEVA) Stock Fair Value Rises As Analysts Back CNS Transformation
Yahoo - 2026-10-05
What You Need to Know Ahead of Deckers Outdoor’s Earnings Release
Yahoo - 2026-10-02
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Fintel - 2026-10-02
Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 19.98% to $0.13
Benzinga - 2026-10-02
Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026
Yahoo - 2026-10-01
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
Yahoo - 2026-10-01
Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion
Benzinga - 2026-10-01
This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga - 2026-10-01
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55
ChartMill - 2026-10-01
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup
Yahoo - 2026-10-01
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Yahoo - 2026-09-30
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Yahoo - 2026-09-30
Here's Why You Should Add URGN Stock to Your Portfolio Now
Yahoo - 2026-09-29
Teva's Branded Drugs Take Center Stage in Its Growth Strategy
Yahoo - 2026-09-29
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
Yahoo - 2026-09-28
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Benzinga - 2026-09-28
Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer
Yahoo - 2026-09-23
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Yahoo - 2026-09-23
Teva Releases Q3 2026 Aide Memoire
Yahoo - 2026-09-23
Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says
Yahoo - 2026-09-23
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
Yahoo - 2026-09-23
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
SeekingAlpha - 2026-09-23
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Benzinga - 2026-09-23
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50
Yahoo - 2026-09-22
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline
SeekingAlpha - 2026-09-22
Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript
Yahoo - 2026-09-21
Teva Pharmaceutical Industries (TEVA), Why Is It Back In The Spotlight?
Yahoo - 2026-09-21
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
Yahoo - 2026-09-18
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Benzinga - 2026-09-18
Teva Pharmaceuticals Presents Data Showing Healthcare Providers Prioritize Drowsiness Risk, Long-Term Response And Drug Interactions When Treating Older TD Patients
Benzinga - 2026-09-18
Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder
Benzinga - 2026-09-18
Teva Presents New SOLARIS Data Showing TEV-'749 Maintained Schizophrenia Stabilization And Supported Remission In Long-Term Use
Benzinga - 2026-09-18
Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis
Yahoo - 2026-09-16
Most Active Options Report: FPS, TEVA, AFL
Yahoo - 2026-09-16
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
Yahoo - 2026-09-16
Remepy Welcomes Pharma R&D Leader, Eran Harary, MD, as Chief Medical Officer, to Advance Hybrid Drug™ Pipeline
Benzinga - 2026-09-15
Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed
Yahoo - 2026-09-14
Teva CEO on the company’s NYSE debut and what's next
SeekingAlpha - 2026-09-14
Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Yahoo - 2026-09-14
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars
Yahoo - 2026-09-14
Temporal Raises $550 Million in Series E Round: NYSE Content Update
Yahoo - 2026-09-14
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Yahoo - 2026-09-12
Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Benzinga - 2026-09-10
Teva Priced Approximately $4.9B (Equivalent) of Senior Notes
Benzinga - 2026-09-09
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45
Yahoo - 2026-09-07
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
Yahoo - 2026-09-07
Teva Announces Launch of Offering of Senior Notes
SeekingAlpha - 2026-09-04
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - Slideshow
Yahoo - 2026-09-04
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
Yahoo - 2026-09-04
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Benzinga - 2026-09-04
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
Yahoo - 2026-09-03
Outperforming Pharma Stock Still Has Upside Potential
Yahoo - 2026-09-03
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Yahoo - 2026-09-02
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Yahoo - 2026-09-02
Teva’s mAb shows benefit in celiac disease study
SeekingAlpha - 2026-09-02
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript
Yahoo - 2026-09-02
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
Yahoo - 2026-09-02
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
Yahoo - 2026-09-02
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Benzinga - 2026-09-02
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Yahoo - 2026-09-01
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
Yahoo - 2026-09-01
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Yahoo - 2026-09-01
Mid-cap biotechs join Trump’s latest round of drug pricing deals
Yahoo - 2026-09-01
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
Yahoo - 2026-08-31
Trump's Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing
Yahoo - 2026-08-31
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
Yahoo - 2026-08-31
Trump Announces Drug Pricing Deals with Teva, 8 Other Companies
Benzinga - 2026-08-31
Teva And Trump Administration Commit To Lowering Select Medicaid Drug Costs
Benzinga - 2026-08-31
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Benzinga - 2026-08-28
BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
Benzinga - 2026-08-28
BioXcel Therapeutics Kicks Off DoD-Funded Phase 2a Study Of BXCL501 For Acute Stress Reactions, Led By UNC Institute For Trauma Recovery
Benzinga - 2026-08-26
Major Update: Amir Weiss At Teva Pharmaceutical Indus Exercises Options, Realizing $46K
SeekingAlpha - 2026-08-20
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Benzinga - 2026-08-20
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Benzinga - 2026-08-19
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Benzinga - 2026-08-19
Teva Pharmaceuticals' New Drug Application For Ecopipam Gets FDA Acceptance To Treat Pediatric Patients With Tourette Syndrome
Benzinga - 2026-08-12
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42
SeekingAlpha - 2026-08-05
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
SeekingAlpha - 2026-08-03
Teva's Re-Rating Still Has Room To Run
SeekingAlpha - 2026-08-03
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
SeekingAlpha - 2026-07-31
Teva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha - 2026-07-31
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course
SeekingAlpha - 2026-07-31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Yahoo - 2026-07-29
Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations
Yahoo - 2026-07-29
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...
SeekingAlpha - 2026-07-29
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Yahoo - 2026-07-29
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Benzinga - 2026-07-29
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Yahoo - 2026-07-29
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Yahoo - 2026-07-29
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
Yahoo - 2026-07-29
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
Yahoo - 2026-07-29
‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness
Benzinga - 2026-07-29
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate
Yahoo - 2026-07-28
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics
Benzinga - 2026-07-28
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44
Yahoo - 2026-07-26
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
Yahoo - 2026-07-23
Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat
Yahoo - 2026-07-22
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
SeekingAlpha - 2026-07-18
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2026 Update
SeekingAlpha - 2026-07-16
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Yahoo - 2026-07-15
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
SeekingAlpha - 2026-07-15
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
SeekingAlpha - 2026-07-14
Organon & Co: Great Odds, Small Prize, Big Penalty
Yahoo - 2026-07-14
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress
Yahoo - 2026-07-13
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2027 Earnings Results
Benzinga - 2026-07-13
U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement Agreement
Yahoo - 2026-07-13
Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings
Yahoo - 2026-07-13
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
SeekingAlpha - 2026-07-09
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b - Slideshow
Benzinga - 2026-07-09
Teva Pharmaceuticals International Granted Exclusive Rights To Commercialize Formulations For Polpharma Biologics’ Proposed Biosimilar To Ocrevus
Benzinga - 2026-07-09
Teva Pharmaceutical Industries And Samsung Bioepis Partner To Commercialize OPUVIZ Aflibercept Biosimilar In Canada
Benzinga - 2026-07-08
Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country’
SeekingAlpha - 2026-07-07
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript
Benzinga - 2026-07-07
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
SeekingAlpha - 2026-06-28
Teva Pharmaceutical's Innovative Shift Continues With Ecopipam Addition
Benzinga - 2026-06-16
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
SeekingAlpha - 2026-06-08
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
SeekingAlpha - 2026-06-08
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Benzinga - 2026-06-08
Teva Pharma Announces New Data Highlighting Comprehensive Tardive Dyskinesia Symptom Improvement From Treatment With AUSTEDO And AUSTEDO XR
Benzinga - 2026-06-05
10 Health Care Stocks Whale Activity In Today's Session
Benzinga - 2026-06-05
Teva Pharma Announces New Data From Real-World, Decentralized Study Demonstrating AUSTEDO Improves Quality Of Life In HD's Chorea Patients And Caregivers
Benzinga - 2026-06-04
Teva Pharmaceutical Industries Introduces AHZANTIVE In Europe To Expand Footprint In Ophthalmology
Yahoo - 2026-06-02
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
Yahoo - 2026-06-01
Teva to Present at the Goldman Sachs Global Healthcare Conference
Yahoo - 2026-06-01
Is Veeva (VEEV) Quietly Redefining Its Moat With Deeper AI-Driven Life Sciences Integration?
Yahoo - 2026-06-01
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks
ChartMill - 2026-05-30
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings
Yahoo - 2026-05-30
A Look At Teva (TEVA) Valuation After New Real World Tardive Dyskinesia Data Release
Yahoo - 2026-05-28
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
Yahoo - 2026-05-27
Teva Pharmaceuticals Commits to Veeva Vault CRM
Yahoo - 2026-05-27
Interact Enters a New Era of Growth with Brand Evolution, AI Innovation, and Industry Recognition
Benzinga - 2026-05-25
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
SeekingAlpha - 2026-05-24
Teva's Growth Story Is No Longer Just Generic, It's Getting Branded
Yahoo - 2026-05-22
TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU
Yahoo - 2026-05-19
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Yahoo - 2026-05-19
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Yahoo - 2026-05-18
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
Yahoo - 2026-05-18
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
Benzinga - 2026-05-18
Teva Pharmaceutical Industries Announces New Data Highlighting Significant Gap In Diagnosing Tardive Dyskinesia In Teen Patients With Underlying Mood Disorders
Yahoo - 2026-05-16
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal
Yahoo - 2026-05-15
Is It Too Late To Consider Teva Pharmaceutical Industries (TEVA) After Its 3‑Year Rally?
Yahoo - 2026-05-15
Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech
Yahoo - 2026-05-15
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.
SeekingAlpha - 2026-05-13
Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain
SeekingAlpha - 2026-05-11
Teva's CNS Portfolio Is Growing, But Valuation Is Stretched
Benzinga - 2026-05-06
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40
Benzinga - 2026-05-01
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga - 2026-04-30
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40
Benzinga - 2026-04-30
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42
Benzinga - 2026-04-30
Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42
Benzinga - 2026-04-30
Truist Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $45
SeekingAlpha - 2026-04-29
Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript
Benzinga - 2026-04-29
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan
Benzinga - 2026-04-29
Teva Pharmaceutical Indus Q1 2026 Earnings Call Transcript
SeekingAlpha - 2026-04-29
Teva Pharmaceutical Industries Limited 2026 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-04-29
Earnings Scheduled For April 29, 2026
Benzinga - 2026-04-29
Teva Pharmaceutical Indus Affirms FY2026 Adj EPS Guidance of $2.57-$2.77 vs $2.67 Est; Affirms FY2026 Sales Guidance of $16.400B-$16.800B vs $16.570B Est
Benzinga - 2026-04-29
Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate
Benzinga - 2026-04-29
Teva Pharmaceuticals To Acquire Emalex Biosciences For $700M In Cash, With Emalex Shareholders Eligible To Receive Up To $200M In Future Commercial Milestones And Ecopipam Royalties
SeekingAlpha - 2026-04-21
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
SeekingAlpha - 2026-04-17